Eculizumab with trade name Soliris, is an FDA-approved drug to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5. Eculizumab specifically binds to the terminal complement component 5, or C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.
Anti-Eculizumab Antibody (4F6), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Eculizumab.
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Synonyms: Mouse monoclonal to Eculizumab/Soliris
Description: Eculizumab with trade name Soliris, is an FDA-approved drug to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5. Eculizumab specifically binds to the terminal complement component 5, or C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. Anti-Eculizumab Antibody (4F6), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Eculizumab.
Host Species: Mouse
Conjugation: Unconjugated
Immunogen: Eculizumab
Purification: Protein A affinity column
Clone: 4F6
Properties
- Subclass IgG1,K Concentration 0.5 mg/ml, lyophilized with PBS, pH 7.2, containing 0.02% sodium azide.
- Reconstitution Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
- Specificity The product is specific for Eculizumab.
- Storage The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
- Note GenScript can customize this product per customer's request including product size, buffer components, etc.
Applications
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
ELISA detection: 0.01-1 µg/ml
Other applications: user-optimized